ArticleEMBO reports2013
Complex diseases require complex therapies.
Article in EMBO reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases.Nature biomedical engineering · 2025Article
- Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence.United European gastroenterology journal · 2024Review
- Artificial intelligence: A new tool in the pathologist's armamentarium for the diagnosis of IBD.Computational and structural biotechnology journal · 2024Review
- Focus on Achalasia in the Omics Era.International journal of molecular sciences · 2024Review
- A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.Nature communications · 2024Article
- Review
- Omics and Multi-Omics in IBD: No Integration, No Breakthroughs.International journal of molecular sciences · 2023Review
- A Holistic Perspective on How Photobiomodulation May Influence Fatigue, Pain, and Depression in Inflammatory Bowel Disease: Beyond Molecular Mechanisms.Biomedicines · 2023Article
- Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease.Biomedicines · 2023Article
- Systems biology platform for efficient development and translation of multitargeted therapeutics.Frontiers in systems biology · 2023Article
- RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.Frontiers in oncology · 2023Review
- Review
- Inflammatory Bowel Disease Therapy: Beyond the Immunome.Frontiers in immunology · 2022Article
- Article
- DeepBindRG: a deep learning based method for estimating effective protein-ligand affinity.PeerJ · 2019Article
- Multifunctional Platinum@BSA-Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation.ACS omega · 2018Article
- Human aging and disease: Lessons from age-related macular degeneration.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Inflammatory Bowel Disease: Complexity and Variability Need Integration.Frontiers in medicine · 2018Article
- Autophagy in Neutrophils: From Granulopoiesis to Neutrophil Extracellular Traps.Frontiers in cell and developmental biology · 2018Review
- The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.Nature reviews. Gastroenterology & hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.